Achillion shares soar as potential treatment seen as hep C cure

(Reuters) - Achillion Pharmaceuticals Inc said it would test a combination of two of its experimental hepatitis C drugs after they showed promise against the virus in separate studies. The biotechnology company's shares shot up about 60 percent to $22.76 in premarket trading on Monday. The first study, testing a combination of 50 mg of Achillion's ACH-3102 and 400 mg of Gilead Sciences Inc's Sovaldi, showed the regimen sustained a cure in patients for four weeks following therapy. ...



via Health News Headlines - Yahoo News http://ift.tt/1zoo9DX